The DIVE/DPV registries: evolution of empagliflozin use in clinical practice in Germany

The DIVE/DPV registries: evolution of empagliflozin use in clinical practice in Germany

Introduction Empagliflozin reduced morbidity and mortality in patients with type 2 diabetes mellitus (T2DM) in clinical trials. A registry study was undertaken to describe evolution of patient characteristics and assess the real-world effectiveness/safety of empagliflozin.Research design and methods...

Full description

Bibliographic Details
Main Authors: Thomas Danne, Jochen Seufert, Christian Wagner, Kerstin König, Dirk Raddatz, Rosmarie Weber-Lauffer, Diether Erath, Jost Hilgenberg, Carsten Spies, Maximilian Gabler, Johannes Foersch, Ludwin Ley
Format: Article
Language:English
Published: BMJ Publishing Group 2020-04-01
Series:BMJ Open Diabetes Research & Care
Online Access:https://drc.bmj.com/content/8/1/e001486.full

Internet

https://drc.bmj.com/content/8/1/e001486.full

Similar Items